 OncoSec Medical Incorporated NASDAQ:ONCS the Company or OncoSec, a company developing late-stage intratumoral DNAbased cancer immunotherapies, today announced that Providence Cancer Institute, a part of Providence St. Joseph Health Providence, is pursuing a first-in-human Phase 1 clinical trial of OncoSecs novel DNAencodable, investigational vaccine, CORVax12, which is designed to act as a prophylactic vaccine to prevent COVID-19. CORVax12 consists of OncoSecs existing product candidate, TAVOTM interleukin-12 or IL-12 plasmid, in combination with an immunogenic component of the SARS-CoV-2 virus recently developed by researchers at NIHs National Institute of Allergy and Infectious Diseases NIAID and licensed to OncoSec on a non-exclusive basis. 